0000899243-19-030015.txt : 20191223 0000899243-19-030015.hdr.sgml : 20191223 20191223210709 ACCESSION NUMBER: 0000899243-19-030015 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191220 FILED AS OF DATE: 20191223 DATE AS OF CHANGE: 20191223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bauer Jake CENTRAL INDEX KEY: 0001654909 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37609 FILM NUMBER: 191307918 MAIL ADDRESS: STREET 1: C/O MYOKARDIA, INC. STREET 2: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MyoKardia Inc CENTRAL INDEX KEY: 0001552451 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455500552 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-741-0900 MAIL ADDRESS: STREET 1: 333 ALLERTON AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-20 0 0001552451 MyoKardia Inc MYOK 0001654909 Bauer Jake C/O MYOKARDIA INC. 333 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief Business Officer Common Stock 2019-12-20 4 M 0 10000 9.08 A 54998 D Common Stock 2019-12-20 4 M 0 7500 13.90 A 62498 D Common Stock 2019-12-20 4 S 0 18916 70.0688 D 43582 D Stock Option (Right to Buy) 9.08 2019-12-20 4 M 0 10000 0.00 D 2026-02-01 Common Stock 10000 8748 D Stock Option (Right to Buy) 13.90 2019-12-20 4 M 0 7500 0.00 D 2027-07-19 Common Stock 7500 0 D This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Represents the weighted average sale price of the shares sold ranging from $70.00 to $70.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. The shares subject to this option vest and become exercisable in 48 equal monthly installments from January 1, 2016, subject to the Reporting Person's continued service to the Issuer through each vesting date. The shares subject to this option vested in two annual installments after July 20, 2017. /s/ Cynthia Ladd, as Attorney-in-Fact 2019-12-23